How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses

European Neuropsychopharmacology

Volumn 24, Issue 8, 2014, Pages 1279-1288

  Marques, Tiago Reis ^a   Levine, Stephen Z ^b   Reichenberg, Avi ^a,c   Kahn, Rene ^d   Derks, Eske M ^e   Fleischhacker, Wolfgang W ^f   Rabinowitz, Jonathan ^g   Kapur, Shitij ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF HAIFA   (Israel)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g BAR ILAN UNIVERSITY   (Israel)

Author keywords

Antipsychotic response; Antipsychotics; Factor analysis; Schizophrenia; Symptom dimensions

Indexed keywords

AMISULPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CHRONIC PATIENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; STRUCTURAL EQUATION MODELING; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; ANXIETY; CLINICAL TRIAL (TOPIC); COMPLICATION; DEPRESSION; FACTORIAL ANALYSIS; SOCIAL PROBLEM;

ANALYSIS OF VARIANCE; ANOMIE; ANTIPSYCHOTIC AGENTS; ANXIETY; CLINICAL TRIALS AS TOPIC; DEPRESSION; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 84904907964     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.04.001     Document Type: Article

References (37)

1. Crow T.J. Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry 1980, 137:383-386.
2. Crow T.J. Molecular pathology of schizophrenia: more than one disease process?. Br. Med. J. 1980, 280(6207):66-68. (Review).
3. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148(11):1474-1486. (Review).
4. Goghari V.M., Sponheim S.R., MacDonald A.W. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci. Biobehav. Rev. 2010, 34(3):468-486.
5. Gründer G., Hippius H., Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 2009, 8(3):197-202. (Review).
6. Hamann J., Kolbe G., Cohen R., Leucht S., Kissling W. How do psychiatrists choose among different antipsychotics?. Eur. J. Clin. Pharmacol. 2005, 61(11):851-854.
7. Hamshere M.L., Holmans P.A., McCarthy G.M., Jones L.A., Murphy K.C., Sanders R.D., Gray M.Y., Zammit S., Williams N.M., Norton N., Williams H.J., McGuffin P., O'Donovan M.C., Craddock N., Owen M.J., Cardno A.G. Phenotype evaluation and genomewide linkage study of clinical variables in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B(8):929-940.
8. Hu L.-T., Bentler P.M. Evaluating Model Fit. Structural Equation Modelling: Concepts, Issues and Applications 1995, 76-99. Thousand Oaks, CA: Sage. R.E. Hoyle (Ed.).
9. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63(10):1079-1087.
10. Jor̈reskog K.G., Sor̈rbom D. LISREL 8: Structural Equation Modeling with the SIMPLIS Command Language 1993, Scientific Software, Chicago.
11. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097. EUFEST study group.
12. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(7):1081-1090. (Review).
13. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
14. Kim D.H., Maneen M.J., Stahl S.M. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 2009, 6(1):78-85. (Review).
15. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14(4):429-447. (Review).
16. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
17. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Asenjo Lobos C., Schwarz S., Davis J.M. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166(2):152-163.
18. Leucht S., Pitschel-Walz G., Engel R.R., Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 2002, 159(2):180-190.
19. Levine S.Z., Petrides K.V., Davis S., Jackson C.J., Howell P. The use of structural equation modeling in stuttering research: concepts and directions. Stammering Res. 2005, 1(4):344-363.
20. Levine S.Z., Rabinowitz J. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. J. Clin. Psychopharmacol. 2007, 27(5):431-436.
21. Lieberman J.A., Dunbar G., Segreti A.C., Girgis R.R., Seoane F., Beaver J.S., Duan N., Hosford D.A. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013, 38(6):968-975.
22. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
23. Lindenmayer J.P., Grochowski S., Hyman R.B. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995, 14(3):229-234.
24. Mallinckrodt C.H., Clark W.S., David S.R. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 2001, 11(1-2):9-21.
25. Mallinckrodt C.H., Clark W.S., David S.R. Type I error rates from mixed effects model repeated measures versus fixed effects Anova with missing values imputed via last observation carried forward. Drug Inf. J. 2001, 35:1215-1225.
26. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58(12):538-546.
27. Marder S.R., Meibach R.C. Risperidone in the treatment of Schizophrenia. Am. J. Psychiatry 1994, 151:825-835.
28. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10(1):79-104. (Review).
29. Nakaya M., Suwa H., Ohmori K. Latent structures underlying schizophrenic symptoms: a five-dimensional model. Schizophr. Res. 1999, 39(1):39-50. (Review).
30. Miyamoto S., Jarskog L.F., Fleischhacker W.W Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr. Opin. Psychiatry 2013, 26(2):158-165. (Review). 10.1097/YCO.0b013e32835d8296.
31. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry 1995, 166(6):712-726.
32. Rabinowitz J., Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr. Bull. 2008, 34(2):286-291.
33. Roth B.L., Sheffler D.J., Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 2004, 3(4):353-359. (Review).
34. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., McGorry P.D., Van Hove I., Eerdekens M., Swyzen W., De Smedt G. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 2005, 162(5):947-953.
35. Shim S.S., Hammonds M.D., Kee B.S. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(1):16-27. (Review).
36. Sorg C., Manoliu A., Neufang S., Myers N., Peters H., Schwerthöffer D., Scherr M., Mühlau M., Zimmer C., Drzezga A., Förstl H., Bäuml J., Eichele T., Wohlschläger A.M., Riedl V. Increased intrinsic brain activity in the striatum reflects symptom dimensions in schizophrenia. Schizophr. Bull. 2013, 39(2):387-395.
37. Wong E.H., Yocca F., Smith M.A., Lee C.M. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. Int. J. Neuropsychopharmacol. 2010, 13(9):1269-1284.